Addus HomeCare (ADUS) RBC Capital Markets Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
RBC Capital Markets Global Healthcare Conference 2026 summary
24 May, 2026Regulatory and compliance environment
Recent moratorium on new Home Health licensure does not impact PCS operations or acquisition strategy.
Compliance investments and robust internal controls position the company favorably with payers and regulators.
Ongoing collaboration with government and industry groups to address fraud and abuse is seen as beneficial.
No significant expected impact on valuations or business operations from current regulatory actions.
Operational and growth trends
PCS census growth continues in Illinois, Texas, and New Mexico, with starts of care exceeding discharges.
Same-store billable hours per business day remain in the 2%-2.5% range, with potential to reach higher levels if rate support improves.
Caregiver app rollout in major states has improved fill rates, with Texas expected to see gains similar to Illinois.
Bridge Programs are driving 20%-30% of hospice admissions from Home Health in key markets.
M&A and market expansion
Indiana acquisitions provide a new foothold, with nearly $20 million in revenue and further expansion opportunities.
Company is well-positioned for large PCS-driven acquisitions, with a clean balance sheet and capacity for all-cash deals.
Valuations for potential deals are trending below double digits, reflecting current market multiples.
Latest events from Addus HomeCare
- Q2 2026 revenue rose 8% to $377.4M, with net income up 25.2% and strong cash flow fueling growth.ADUS
Q2 2026 - All agenda items, including director elections and auditor ratification, were approved.ADUS
AGM 2026 - Census and hours growth accelerate with tech adoption, supporting balanced expansion and M&A.ADUS
Bank of America Global Healthcare Conference 2026 - Q1 2026 revenue up 7.7%, net income up 18.1%, driven by personal care and hospice growth.ADUS
Q1 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with strong governance focus.ADUS
Proxy filing - Q3 revenue up 7%, EPS up 13%, Gentiva deal to close Q4, New York exit, liquidity strong.ADUS
Q3 2024 - Q2 revenue up 10.4%, net income up 21.7%, and $350M Gentiva acquisition announced.ADUS
Q2 2024 - Regulatory clarity, strong hiring, and M&A focus drive growth and expansion plans.ADUS
Jefferies 2024 Global Healthcare Conference - Q1 2025 delivered 20% revenue growth and margin gains, led by personal care and acquisitions.ADUS
Q1 2025